Logo: Qwo | Collagenase clostridium histolyticum-aaes. Injection 0.92 mg.

A Little Qwo & Tell

You’re invited to a virtual Lunch & Learn sponsored by Endo Aesthetics.

At this event, QWO investigator Sachin Shridharani, MD will reveal more about QWO, the first and only FDA-approved injectable for moderate to severe cellulite in the buttocks of adult women. This event will also include an interactive Q&A session with the Endo team. Lunch will be provided by VCS. Limited to the first 50 registrants.

Event Registration Download Vegas Backgrounds
Headshot of Sachin Shridharani, MD.

Sachin Shridharani, MD

Event Details

Saturday, September 26
11:15 – 11:45 a.m. PDT
At the 2020 Virtual VCS

Register for Event

Your registration is now complete. To receive your lunch provided by VCS click the link below. Limited to the first 50 registrants

Reserve Your Lunch
Email Subscription Form

Please check the fields below.

*Required Field

Endo Aesthetics LLC understands that your privacy is important. By providing your information and clicking the Register Now button, you are giving Endo Aesthetics and other parties working with us permission to communicate with you. We will send you up-to-date information, as well as future Endo Aesthetics information that may be of interest. We will not sell the information you provide to any party for its marketing use. To view our privacy policy, please visit www.endo.com/privacy-legal.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

There was a problem with your request. Please try again later.

Bringing You a Bit of Vegas

Because we’re going to be missing the sights and sounds of the Las Vegas Strip, we’re offering downloadable QWO backgrounds to bring you some Vegas feels throughout your conference experience.

We can’t wait to give you a sneak peek behind the curtains at QWO, the latest treatment from Endo Aesthetics.

INDICATION

QWO is indicated for the treatment of moderate to severe cellulite in the buttocks of adult women.

IMPORTANT SAFETY INFORMATION FOR QWO

CONTRAINDICATIONS

QWO is contraindicated in patients with a history of hypersensitivity to collagenase or to any of the excipients or the presence of infection at the injection sites.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Serious hypersensitivity reactions including anaphylaxis have been reported with the use of collagenase clostridium histolyticum. If such a reaction occurs, further injection of QWO should be discontinued and appropriate medical therapy immediately instituted. Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions.

Injection Site Bruising

In clinical trials, 84% of subjects treated with QWO experienced injection site bruising. Subjects with coagulation disorders or using anticoagulant or antiplatelet medications (except those taking ≤150 mg aspirin daily) were excluded from participating in Trials 1 and 2.

QWO should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet (except those taking ≤150 mg aspirin daily) or anticoagulant therapy.

Substitution of Collagenase Products

QWO must not be substituted with other injectable collagenase products.

QWO is not intended for the treatment of Peyronie’s Disease or Dupuytren’s Contracture.

ADVERSE REACTIONS

In clinical trials, the most commonly reported adverse reactions in patients treated with QWO incidence ≥ 10% were at the injection site: bruising, pain, nodule and pruritus.

Please see Full Prescribing Information for QWO.